Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

"The completion of enrollment for the 201 Trial in untreated Parkinson's disease represents a major milestone for Inhibikase," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "This achievement reflects the hard work of our team, the success of our proprietary and innovative patient identification and referral service and the commitment of our 32 U.S. study sites to evaluating potential diseasemodifying solutions for patients with this debilitating disease. With enrollment in ...